STRO-006 for advanced solid tumors that have resisted treatment
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called STRO-006 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective for cancers like head and neck, lung, stomach, colorectal, endometrial, bladder, and breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of cancer listed in the study, such as head and neck, lung, stomach, colorectal, endometrial, bladder, or breast cancer.
- Your cancer must have come back or spread despite prior treatment (refractory, recurrent, or metastatic).
- If you're in the expansion part of the study, you can have had at most two prior treatments (or up to four for certain lung cancers).
- You need to be in fairly good physical condition (ECOG score of 0 or 1) and have a life expectancy of at least 3 months.
- You must not have had a certain type of antibody-drug conjugate (ADC) therapy with a TOP1 inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
This trial tests a new drug, SI-B036-ST-101, for people with advanced cancer that has spread or cannot be removed with surgery. It aims to see if the drug is safe and effective for several cancer types, including lung cancer, melanoma, and ovarian cancer.
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.